A Study to Assess the Safety, Tolerability and Efficacy of RG2417 in Bipolar I Depression

Bipolar I Depression Clinical Trial

Official title:
A Phase II Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Study to Assess the Safety, Tolerability and Efficacy of RG2417 (Uridine) in the Treatment of Bipolar I Depression

Status Completed

Clinical Trial Summary

The purpose of this study is to test a new drug, RG2417, to see how the drug affects symptoms of bipolar I depression and to make sure it is safe in humans.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00812058
Study type	Interventional
Source	Repligen Corporation
Contact
Status	Completed
Phase	Phase 2
Start date	November 2008
Completion date	December 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02046369` - Lurasidone Pediatric Bipolar Study	Phase 3
Completed	`NCT00481195` - Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder	Phase 2
Completed	`NCT01403662` - Evaluating the Efficacy of Adjunctive Minocycline for the Treatment of Bipolar Depression	Phase 3
Recruiting	`NCT03336918` - Lithium Effects on the Brain's Functional and Structural Connectome in the Treatment of Bipolar Disorder
Terminated	`NCT04383691` - A Study of Lurasidone Compared With Placebo for the Treatment of Bipolar I Depression	Phase 3